NCT05418426已完成1 期
A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80μg Estradiol/4mg Progesterone and 160μg Estradiol/8mg Progesterone Intravaginal Rings) in Healthy PostMenopausal Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- To Determine the Steady State Concentration (Css) for Estradiol
研究概览
简要总结
An open-label study to assess the PK of estradiol, estrone and progesterone from the DARE-HRT1 intravaginal rings at two different dose strengths.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Postmenopausal women with body mass index >/= 18 and </= 38 kg/m2
- •Normal cervix and vagina
- •An intact uterus
- •An acceptable results from an endometrial biopsy
- •normal mammogram report within 24 months of screening
排除标准
- •Prior abnormal cervical screening test (CST) or Pap result within 2 years of screening. Subject can have atypical squamous cells of undetermined significance (ASCUS), if HPV negative.
- •Subjects with any self-reported active sexually transmitted disease and/or evidence of infection based on visual vaginal exam by the investigator
- •Subjects with a UTI during screening as assessed by urine dipstick test with abnormal test findings (any positive result for leukocytes AND any positive result for nitrites)
- •Subjects with > 4 mm endometrium lining at screening (on the transvaginal ultrasound)
- •Have a history of endometrial hyperplasia or cervical or uterine carcinoma
- •Subjects with indwelling catheters or requiring intermittent catheterization
- •Subjects with multiple or unsuccessful (e.g., still having symptoms) pelvic reconstructive surgery, or suffers from pelvic relaxation
- •Subjects who have had a hysterectomy
- •Subjects taking any estrogen and/or progesterone products (see Section 4.1 for washout requirements)
- •Subjects with concomitant use of personal lubricants (water-based lubricants are allowed) or any intravaginal product or medication, either by prescription or over-the-counter (e.g., Femring [estradiol acetate vaginal ring], ESTRING® [estradiol vaginal ring]) with the exception of those who agree not to use these products during the IVR use period
- •Self-reported or observed vaginal irritation; vaginal, vulvar, or cervical lesions, undiagnosed vaginal bleeding; or tenderness
- •Subjects with a finding of clinically significant uterine fibroids at screening
- •Subjects with a known hypersensitivity to progesterone, estradiol, Femring, or the components of the IVR (e.g., ethylene vinyl acetate)
- •Subjects with known hypersensitivity to peanuts (Prometrium capsules contain peanut oil)
- •Subjects with prior pelvic malignancies
- •Subjects with a history of any severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or study treatment administration or could interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into the trial. This includes but is not limited to the following:
- •Human immunodeficiency virus (HIV) infection (confirmed by medical history/ serology testing)
- •Active chronic hepatitis B or hepatitis C infection including hepatitis B surface antigen and hepatitis C antigen positive subjects with or without abnormal liver enzymes (confirmed by medical history/serology testing)
- •Concurrent neurodegenerative disease
- •Cardiovascular: uncontrolled hypertension, unstable angina, myocardial infarction or symptomatic congestive heart failure within the past 6 months, serious uncontrolled cardiac arrhythmia, use of Class 1 antiarrhythmic medications, or history of venous thromboembolism or stroke
- •Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of the protocol
- •History of gallbladder disease unless gallbladder removed
- •Symptomatic bacterial vaginosis
- •Have fasting triglyceride of > 300 mg/dL and/or total cholesterol of > 300 mg/dL
- •AST or ALT > 1.5 times the upper limit of normal
- •Fasting glucose > 125 mg/dL
- •Evidence of current alcohol or drug abuse in the past 60 days including a positive result from the urine drugs of abuse or alcohol screen, or history of drug or alcohol dependence in the last two years, as assessed by principal investigator. Alcohol abuse is defined as greater than 14 standard units/week for females and drug abuse is defined as known psychiatric or substance abuse disorder that would interfere with participation with the requirements of this study, including current use of any illicit drugs.
- •Participation in any other investigational drug or device trial in which administration of an investigational study drug/device occurred within 30 days or placement of a non-drug eluting medical device within 15 days prior to screening.
研究组 & 干预措施
Oracle Estrace(R)/Prometrium(R)
Active Comparator
29 days (estradiol 1mg/progesterone 100 mg oral capsule)
干预措施: Oral Reference (Drug)
IVR: estradiol 80 ug/day + progesterone 4mg/day
Experimental
28-day IVR 80/4
干预措施: IVR Dose 1 (Device)
IVR: estradiol 160 ug/day + progesterone 8mg /day
Experimental
28-day IVR 160/8
干预措施: IVR Dose 2 (Device)
结局指标
主要结局
To Determine the Steady State Concentration (Css) for Estradiol
时间窗: 28 days
To describe the Pharmacokinetic parameters of estradiol in dose combinations (Estradiol 80 ug/progesterone 4/mg day and Estradiol 160 ug/progesterone 8/mg day)
To Determine the Stead State Concentration (Css) for Estrone
时间窗: 28 days
To describe the Pharmacokinetic parameters of estrone in dose combinations (Estradiol 80 ug/progesterone 4/mg day and Estradiol 160 ug/progesterone 8/mg day)
To Determine the Steady State Concentration (Css) for Progesterone
时间窗: 28 days
To describe the Pharmacokinetic parameters of progesterone in dose combinations (Estradiol 80 ug/progesterone 4/mg day and Estradiol 160 ug/progesterone 8/mg day)
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome (CPDR001X2105)bloodcell cancerbonemarrow cancer. AML: Acute myeloide leukemiaMDS: Myelodysplasia10024324NL-OMON55557ovartis5
进行中（未招募）
1 期
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)NCT04676477Daiichi Sankyo246
已完成
1 期
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy VolunteersHealthyNCT01453426Biogen71
已完成
1 期
Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy VolunteersHealthy VolunteersAlzheimer DiseaseNCT04570644AZTherapies, Inc.56
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea PedisTinea CrurisTinea PedisNCT05363449Therapeutics, Inc.42